Brokers Issue Forecasts for Pfizer's Q4 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE - Free Report) - Investment analysts at Zacks Research decreased their Q4 2024 earnings per share estimates for shares of Pfizer in a research note issued to investors on Monday, November 18th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will earn $0.39 per share for the quarter, down from their previous estimate of $0.58. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer's FY2025 earnings at $2.80 EPS.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company's revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.17) earnings per share.

Several other equities research analysts also recently issued reports on the stock. Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 price target on the stock. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $32.92.

Pfizer Stock Down 0.6 %

Shares of NYSE:PFE opened at $24.95 on Thursday. The company has a 50 day moving average of $28.36 and a two-hundred day moving average of $28.61. Pfizer has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $141.36 billion, a price-to-earnings ratio of 33.71, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. FAS Wealth Partners Inc. boosted its holdings in shares of Pfizer by 1.3% during the second quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company's stock worth $736,000 after purchasing an additional 342 shares during the period. Sachetta LLC lifted its position in Pfizer by 7.3% in the 2nd quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company's stock worth $140,000 after buying an additional 342 shares in the last quarter. Wells Trecaso Financial Group LLC boosted its stake in shares of Pfizer by 2.5% during the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock valued at $416,000 after buying an additional 350 shares during the period. Ironvine Capital Partners LLC grew its holdings in shares of Pfizer by 2.1% during the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company's stock valued at $470,000 after acquiring an additional 353 shares in the last quarter. Finally, Secure Asset Management LLC increased its stake in shares of Pfizer by 0.6% in the second quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company's stock worth $1,632,000 after acquiring an additional 353 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the business's stock in a transaction on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company's stock, valued at $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.73%. The ex-dividend date is Friday, November 8th. Pfizer's dividend payout ratio (DPR) is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.